After the FDA rejection of Zurzuvae in one type of depression, and the triple failure of neuro asset dalzanemdor, Sage was ...

The top companies supporting the development of a hydrogen economy for decarbonisation include Linde, Air Liquide, Air ...

DelveInsight's Frontotemporal Dementia Market Insights report includes a comprehensive understanding of current treatment ...

Logo TV, the first 24-hour LGBTQIA+ television network, launched June 30, 2005. Logo's first president reflects on its ...

For Capstan, AbbVie will pay up to $2.1 billion in cash, subject to certain customary adjustments. Capstan is backed by ...

Biogen Inc. closed 46.93% short of its 52-week high of $238.00, which the company achieved on July 12th.

Drug company shares are down amid President Donald Trump’s assault on the industry, but some in Congress see value.

Shares of Biogen Inc. BIIB slipped 1.79% to $124.76 Monday, on what proved to be an all-around positive trading session for ...

“I’m delighted to welcome Anne Marie Cook to Phathom. Her experience and broad skills will be highly impactful as we work to build Phathom into a leading GI company in the coming years,” said Steven ...

Biogen shares fell, after the biotechnology company forecast lower-than-expected revenue and profit for this year, saying multiple-sclerosis drug sales will decline further and will only be ...

Biogen, which currently holds a 10.2% stake in Sage, proposed to acquire all outstanding Sage shares it does not already own for $7.22 per share. In October, the Massachusetts-based company ...

A company representative said there are about 2,500 people worldwide taking Aduhelm. Biogen said it will turn its focus more to other treatments for Alzheimer’s, a fatal, mind-robbing disease.